Bavencio (avelumab)
pCPA File Number:
21433
Negotiation Status:
Concluded with an LOI
Indication(s):
Urothelial carcinoma (UC), first-line maintenance treatment of patients with locally advanced or metastatic whose disease has not progressed with first-line platinum-based induction chemotherapy
Sponsor/Manufacturer:
EMD Serono Canada, a division of EMD Inc.
CDA-AMC Project Number:
PC0225
pCPA Engagement Letter Issued:
Negotiation Process Concluded: